Cutaneous adverse events due to immune checkpoint inhibitors
Immune checkpoint inhibitors, represented by anti-PD-1 antibodies, anti-PD-L1 antibodies and anti-CTLA-4 antibodies, have brought significant therapeutic benefits to many patients with advanced-stage malignancies. By releasing inhibitory signals on T cells, these agents enhance antitumor immune resp...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis Group
2026-07-01
|
| Col·lecció: | Immunological Medicine |
| Matèries: | |
| Accés en línia: | https://www.tandfonline.com/doi/10.1080/25785826.2026.2699471 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|